• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nordisk tumbles on lowered outlook

February 2, 2017 By Sarah Faulkner

Nordisk tumbles on lowered outlookShares in Novo Nordisk (NYSE:NVO) fell -9% this morning after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results and lowered its outlook for 2017.

The Danish company posted profits of 8.7 billion Danish kroner, or $1.26 billion USD, on sales of 29.57 billion kroner for the 3 months ended Dec. 31, for bottom-line growth of 5% compared with the same period last year.

Adjusted to exclude 1-time items, EPS were 3.45 kroner, 2% lower than the consensus on The Street.

Nordisk said it expects to see revenue growth of -1% to 4%, at constant currency rates. The company also widened the range for its operating profit forecast, predicting a range from a -2% decline and a 3% increase.

In October, it pegged flat to low single-digit percentage growth in operating profit and low single-digit growth in sales.

“We are looking at a 2017 plan that is still intact, but we operate in an environment that is increasingly volatile,” CEO Lars Fruergaard Jorgensen said on a conference call, according to Bloomberg.

NVO shares were trading at $33.69 apiece today in mid-morning trading, down -8.2%.

Nordisk and other insulin makers have been under increased pressure this year, as the companies have been repeatedly called out for price hikes.

This week, a class-action lawsuit was filed in the U.S. District Court of Massachusetts, alleging that insulin makers Sanofi (NYSE:SNY), Nordisk and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other based on real market prices.

In the last 5 years, the 3 companies have raised the sticker prices on their drugs by more than 150%, according to the lawsuit. A recent study by the American Medical Association demonstrated that the price of insulin nearly tripled between 2002 and 2013.

Some of the lawsuits’ plaintiffs pay almost $900 each month for their diabetes medications, according to the firm representing the patients, Hagens Berman.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS